Yahoo India Web Search

Search results

  1. Dec 25, 2022 · Synokem Pharama gets CDSCO panel nod to manufacture, market Naftifine HCL Cream 2%. Dr. Divya Colin 22 Dec 2022 12:30 PM GMT. New Delhi: The drug major Synokem Pharmaceutical has got green signal from the Subject Expert Committee (SEC) functional under the Central Drug...

    • Our Team

      At the helm of Medical Dialogues is our core team which is...

    • News

      Medical Dialogues is health news portal designed to update...

  2. Latest Health News. United Doctors Front Association Elects New Leadership for 2024-2025. Medical Dialogues Team 26 Sept 2024 1:30 PM GMT. New Delhi: The United Doctors Front Association (UDFA) recently announced the results of its 2024-2025 internal elections. Issuing a Press...

  3. Jul 6, 2024 · New Delhi: The drug major AstraZeneca Pharma India has got the go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the phase 3 clinical study of the anti-cancer drug Datopotamab deruxtecan (DS-1062a) 100mg/ vial Rilvegostomig (AZD2936) 750 mg/vial (50 mg/ml).

  4. At the helm of Medical Dialogues is our core team which is guided by distinguished mentors from the medical field on our advisory board. In addition, our editorial team is a blend of experts from the medical and journalism field and includes journalists, doctors, and skilled scientific and medical writers.

  5. Medical Dialogues is the new face of medical journalism in India. Our aim is to facilitate free flow of information in the healthcare sector, encourage transparency and connect the industry...

  6. Get your Daily Dose of the Latest Health and Medical Updates at Medical Dialogues. We bring you MD podcast where you can listen to the latest daily medical news of the healthcare sector, discussions and updates about the latest clinical trials and studies, breakdown of important guidelines, and much more.

  7. People also ask

  8. Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content.